Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice

被引:341
作者
Fabre, JE
Nguyen, MT
Latour, A
Keifer, JA
Audoly, LP
Coffman, TM
Koller, BH [1 ]
机构
[1] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA
[2] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
关键词
D O I
10.1038/13522
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Platelet activation is characterized by shape change, induction of fibrinogen receptor expression and release of granular contents, leading to aggregation and plug formation(1). While this response is essential for hemostasis(2), it is also important in the pathogenesis of a broad spectrum of diseases, including myocardial infarction, stroke and unstable angina. Adenosine 5'-diphosphate (ADP) induces platelet aggregation, but the mechanism for this has not been established, and the relative contribution of ADP in hemostasis and the development of arterial thrombosis' is poorly understood. We show here that the purinoceptor P2Y(1) is required for platelet shape change in response to ADP and is also a principal receptor mediating ADP-induced platelet aggregation. Activation of P2Y(1) resulted in increased intracellular calcium but no alteration in cyclic adenosine monophosphate (cAMP) levels. P2Y(1)-deficient platelets partially aggregated at higher ADP concentrations, and the lack of P2Y(1) did not alter the ability of ADP to inhibit cAMP, indicating that platelets express at least one additional ADP receptor. In vivo, the lack of P2Y(1) expression increased bleeding time and protected from collagen- and ADP-induced thromboembolism. These findings support the hypothesis that the ATP receptor P2Y(1) is a principal receptor mediating both physiologic: and pathological ADP-induced processes in platelets.
引用
收藏
页码:1199 / 1202
页数:4
相关论文
共 25 条
  • [1] *ANT TRIAL COLL, 1994, BMJ-BRIT MED J, V308, P159
  • [2] CYTOSKELETAL DOMAINS IN THE ACTIVATED PLATELET
    BEARER, EL
    [J]. CELL MOTILITY AND THE CYTOSKELETON, 1995, 30 (01): : 50 - 66
  • [3] Molecular basis for ADP-induced platelet activation I. Evidence for three distinct ADP receptors on human platelets
    Daniel, JL
    Dangelmaier, C
    Jin, JG
    Ashby, B
    Smith, JB
    Kunapuli, SP
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (04) : 2024 - 2029
  • [4] DIMINNO G, 1983, J PHARMACOL EXP THER, V225, P57
  • [5] P2Y1-receptors in human platelets which are pharmacologically distinct from P2YADP-receptors
    Fagura, MS
    Dainty, IA
    McKay, GD
    Kirk, IP
    Humphries, RG
    Robertson, MJ
    Dougall, IG
    Leff, P
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (01) : 157 - 164
  • [6] ROLE OF PLATELETS IN SMOOTH-MUSCLE CELL-PROLIFERATION AND MIGRATION AFTER VASCULAR INJURY IN RAT CAROTID-ARTERY
    FINGERLE, J
    JOHNSON, R
    CLOWES, AW
    MAJESKY, MW
    REIDY, MA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (21) : 8412 - 8416
  • [7] FREDHOLM BB, 1994, PHARMACOL REV, V46, P143
  • [8] Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors
    Geiger, J
    Hönig-Liedl, P
    Schanzenbächer, P
    Walter, U
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 351 (02) : 235 - 246
  • [9] The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel
    Hechler, B
    Eckly, A
    Ohlmann, P
    Cazenave, JP
    Gachet, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (03) : 858 - 866
  • [10] The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation
    Hechler, B
    Léon, C
    Vial, C
    Vigne, P
    Frelin, C
    Cazenave, JP
    Gachet, C
    [J]. BLOOD, 1998, 92 (01) : 152 - 159